Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); FDA approval of Kyprolis and Increased Takeover Chatter

Baird reiterates an 'Outperform' on Onyx Pharmaceuticals (NASDAQ: ONXX), new price target of $80.00.

Late last Friday, analyst, Christopher Raymond, said, he remains a buyer following the earlier-than-expected FDA approval of Kyprolis in relapsed/refractory multiple myeloma. His checks indicated strong pent up Kyprolis demand, and thinks the stock can work higher near-term as this launch unfolds. Combining this with what he believes will be increased takeout chatter in light of the approval and the positive Nexavar competitive update, we like ONXX shares into the $80-range."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $76.38 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Yageo Corp. (2327:TT) (YAGOY) PT Lowered to NT$656 at HSBC
• L'Oreal SA (OR:FP) (LRLCY) PT Raised to EUR480 at Barclays
• Prysmian SpA (PRY:IM) (PRYMY) PT Raised to EUR53 at HSBC